Pullan's Pieces #116 June 2016 Neuroscience,top 100 VCs, success in CML
Pullan's Pieces #116
June 2016
Global BD News of Biotech and Pharma
Dear Reader,
If you like this newsletter, please sign up to get a monthly email.
SIGN UP HERE TO RECEIVE THESE MONTHLY NEWSLETTERS DIRECTLY IN YOUR INBOX
https://www.robly.com/subscribe?a=09d720be69e6cff000f5ff54cdae0b0bOr send me a note at linda@pullanconsulting.com.
Whoo! Since the last newsletter, there was ASCO and BIO!
Then a good webinar on due diligence, thanks to a great panel! You can watch the recording: http://resources.sharevault.com/webpanel-biopharma-due-diligence-pc
And so many term sheets in the works.
Hard to keep up. But fun!
- Linda Pullan
linda@pullanconsulting.com| 1(805)-558-0361 | www.PullanConsulting.com
Contents:
1.Best partners for big money?
2. Neuroscience snapshot
3. Top 100 VCs
4. Celebrate success in CML
Top Pharma and Big Biotech spend 70%+ of Alliance Deal Money- and Big Biotech pays more
Mark Edwards and the team at BioSci Advisors have again done a very useful analysis of licensing deals and who pays the most.
http://www.bioscibd.com/top-pharma-vs-major-biotech#1
DEAL TERMS OF IN-LICENSING DEALS by TOP PHARMA COMPANIES
Abbott, Abbvie, AZ, Baxter, Bayer, BMS, GSK, Lilly, Merck,
Merck Serono, Novartis, Novo, Pfizer, Roche, Sanofi, Takeda
DEAL TERMS OF IN-LICENSING DEALS by TOP BIOTECH COMPANIES
Actelion, Alexion, Alnylam, Amgen, Biogen, Biomarin,
Celgene, Gilead, Ilumina, Incyte, Ionis, Regeneron, Shire, Vertex
Infographic: Neuroscience Snapshot
Most of the 2015 VC money for US biotechs comes from
California
Massachusetts
New York
And because VCs like to invest close to their offices, that is where most of the money ends up, too.
In the table below for top 100 VCs by 2015 investments,
- NEA tops the list for most money
TPG tops the list for most money per deal
Polaris tops the list for most deals.
- Check out the top 100 in an interactive table at http://endpts.com/the-top-100-biotech-vc-firms
Celebrate an amazing success story- CML
This is why we love our industry! The life expectancy for patients diagnosed with the hematological cancer CML has now improved to match the life expectancy for the general population. This is true for males and females of all ages
If you like this newsletter, please sign up to get a monthly email.
SIGN UP HERE TO KEEP GETTING THE NEWSLETTER:
https://www.robly.com/subscribe?a=09d720be69e6cff000f5ff54cdae0b0b
Or send a note at linda@pullanconsulting.com.